MRI引导的高频(29MHz)经直肠超声引导活检:单中心研究的初步结果
该单中心研究纳入118例至少有一个bp-MRI病灶(评分>2)的男性,行29MHz经直肠显微超声(microUS)二次检查并靶向活检。共分析144个病灶,MRI+/microUS+病灶中检出显著前列腺癌61.4%(70/114),MRI+/microUS-病灶中未检出(0/13),MRI-/microUS+病灶中检出23.5%(4/17)。作者认为microUS作为二次检查可能有助于定位bp-MRI所见病灶。
要点
- microUS二次检查对显著前列腺癌的敏感度为100%,但特异度仅约22.6%–22.8%。
- MRI+/microUS+病灶中61.4%(70/114)检出显著前列腺癌,MRI+/microUS-病灶中为0%(0/13)。
- microUS可能检出bp-MRI未发现的小病灶,MRI-/microUS+病灶中23.5%(4/17)为显著前列腺癌。
核心结论
- 作者认为microUS作为二次检查可能有助于定位bp-MRI所检测到的靶病灶。
研究设计与样本
- 单中心研究,连续纳入118例男性,平均年龄66±13(SD)岁(范围49–93岁),平均前列腺特异性抗原11±19(SD)ng/mL(范围2–200 ng/mL)。
- 纳入标准为bp-MRI上至少有一个评分>2的focal lesion(MRI+);79/118(66.9%)为活检初治,102/118(86.5%)直肠指检无异常。
- 所有患者行MRI引导的29MHz换能器microUS引导活检;microUS可见病灶(microUS+)直接靶向穿刺不使用图像融合,图像融合仅用于MRI+/microUS-病灶。
- 显著前列腺癌定义为Gleason评分≥7或最大癌核心长度>3 mm。
关键影像表现/征象
- 共分析144个focal prostatic lesions,其中MRI+/microUS+ 114个(79.2%),MRI+/microUS- 13个(9%),MRI-/microUS+ 17个(11.8%)。
- MRI+/microUS+病灶中检出显著前列腺癌70个(61.4%),MRI+/microUS-病灶中0个(0%),MRI-/microUS+病灶中4个(23.5%)。
诊断标准与关键数值
- microUS按患者计算的敏感度为100%(95%CI 84.9–100%),特异度为22.8%(95%CI 12.5–35.8%)。
- microUS按病灶计算的敏感度为100%(95%CI 85.1–100%),特异度为22.6%(95%CI 12.3–36.2%)。
- 显著前列腺癌诊断标准为Gleason评分≥7或最大癌核心长度>3 mm。
临床应用与阅片要点
- 作为bp-MRI后的二次检查,microUS引导活检对起源于PZ或TZ下三分之一的显著前列腺癌有100%的检出率,且不使用microUS-MRI图像融合。
- microUS结果可能提供MRI可见病灶的额外信息。
- microUS可能检出bp-MRI未发现的小PZ病灶。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate the ability of high-frequency (29 MHz) transrectal micro-ultrasound (microUS) as a second-look examination after biparametric MRI (bp-MRI) and to reidentify focal lesions seen on diagnostic MRI and to detect new ones METHODS: A total of 118 consecutive men (mean age, 66 ± 13 [SD] years; range, 49-93 years) with a mean prostate-specific antigen level of 11 ± 19 (SD) ng/mL (range, 2-200 ng/mL) and at least one focal lesion (MRI+) with a score > 2 on bp-MRI were included. Of these, 79/118 (66.9%) were biopsy-naïve and 102/118 (86.5%) had non-suspicious rectal examination. All patients had MRI-directed microUS-guided biopsy using a 29-MHz transducer. All lesions visible on micro-ultrasound (microUS+) were targeted without image fusion, which was only used for MRI+/microUS- lesions. Significant prostate cancer (sPCa) was defined by a Gleason score ≥ 7 or a maximum cancer core length > 3 mm.
RESULTS: A total of 144 focal prostatic lesions were analyzed, including 114 (114/144, 79.2%) MRI+/microUS+ lesions, 13 MRI+/microUS- lesions (13/144, 9%), and 17 MRI-/microUS+ lesions (17/144, 11.8%). Significant PCa was detected in 70 MRI+/microUS+ lesions (70/114, 61.4%), in no MRI+/microUS- lesion (0/13, 0%), and in 4 MRI-/microUS+ lesions (4/17, 23.5%). The sensitivity and specificity of microUS on a per-patient and a per-lesion basis were 100% (95% CI, 84.9-100%) and 22.8% (95% CI, 12.5-35.8%) and 100% (95% CI, 85.1-100%) and 22.6% (95% CI, 12.3-36.2%), respectively.
CONCLUSION: MicroUS, as a second-look examination, may show promise to localize targets detected on bp-MRI.
KEY POINTS: • Used as a second-look examination, microUS-guided biopsies have a 100% detection rate of sCa originating in the PZ or lower third of the TZ, without microUS-MRI image fusion. • MicroUS results may provide additional information about lesions visible on MRI. • MicroUS may provide the ability to detect small PZ lesions undetected by bp-MRI.
引用
- Cornud F, Lefevre A, Flam T, et al. MRI-directed high-frequency (29MhZ) TRUS-guided biopsies: initial results of a single-center study. Eur Radiol. 2020. PMID: 32350662. doi:10.1007/s00330-020-06882-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。